Therapeutic potential of the treatment and control of severe recurrent atopic dermatitis
Open Access
- 7 March 2024
- journal article
- review article
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 2,p. 8-16
Abstract
Atopic dermatitis is a hereditary inflammatory skin disease characterized by pruritus, a long recurrent course and certain evolutionary dynamics. Atopic dermatitis of moderate and severe severity is considered a systemic disease that exacerbates the course of associated pathologies, including cardiovascular, neuropsychiatric, and malignant diseases. The current paper presents the essentials about moderate and severe severity atopic dermatitis, statistical epidemiologic and pathogenetic data is thoroughly processed, the issues of the quality of life of such patients are especially accentuated. It is known that a few years ago the therapy of moderate and severe atopic dermatitis was based on systemic corticosteroids and classical immunosuppressants, but they had limited efficacy and were not suitable for long-term treatment due to their safety profile. This article highlights the development of new effective and easy-to-use therapies for atopic dermatitis, which led to the emergence of selective Janus kinase inhibitors. The review presents the way selective inhibitors of Janus kinases works and their effect on the barrier function of the skin. The paper provides the research data on the very first drug from the group of selective inhibitors - upadacitinib, which proved its efficacy on a par with a high degree of safety. The authors presented their own clinical observation of the use of upadacitinib in adolescents with severe atopic dermatitis. The use of upadacitinib in the described clinical cases led to a decrease in the severity of subjective and objective symptoms of inflammatory skin diseases.Keywords
This publication has 26 references indexed in Scilit:
- Association of obesity in early childhood with atopic dermatitis in late childhood and adolescenceJournal of the American Academy of Dermatology, 2022
- Real-world comorbidities of atopic dermatitis in the US adult ambulatory populationJournal of the American Academy of Dermatology, 2022
- Associations between COVID-19 and skin conditions identified through epidemiology and genomic studiesJournal of Allergy and Clinical Immunology, 2021
- Age and eczema severity, but not family history, are major risk factors for peanut allergy in infancyJournal of Allergy and Clinical Immunology, 2021
- Assessment of a causal relationship between body mass index and atopic dermatitisJournal of Allergy and Clinical Immunology, 2021
- Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and AbrocitinibAmerican Journal of Clinical Dermatology, 2020
- Predicting the atopic march: Results from the Canadian Healthy Infant Longitudinal Development StudyJournal of Allergy and Clinical Immunology, 2018
- The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema AssociationJournal of Investigative Dermatology, 2017
- Guidelines of care for the management of atopic dermatitisJournal of the American Academy of Dermatology, 2014
- Atopic dermatitis and the atopic marchJournal of Allergy and Clinical Immunology, 2003